title: [Serum and cerebrospinal concentrations of sICAM-1 sICAM-2, sICAM-3 in neuroborrellosis and tick borne encephalitis--preliminary report].
abstract: OBJECTIVE
  The aim was to evaluate the concentrations of the soluble forms of ICAM-1, ICAM-2, ICAM-3 in the serum and cerebrospinal fluid (CSF) of patients with neuroborreliosis and thick borne encephalitis before and after therapy in comparison with the control group.
  
  
  METHODS
  We examined 30 patients, 10 in each group: neuroborreliosis-group I (NB), tick borne encephalitis--group II (TBE) and in the control group (group K). The diagnosis of neuroborreliosis and TBE based on the clinical features was confirmed by ELISA assays: FSME Virus/TBE Virus test (VIRION, Germany) for TBE and Borrelia IgM and IgG Recombinant (Biomedica Austria) for NB. The assays of sICAM-1, sICAM-2, sICAM-3 (ELISA, Bender Med System, USA) were performed twice in group I and II: before and after 3-4 weeks long treatment and once in control group.
  
  
  CONCLUSIONS
  Increased concentration of soluble forms of ICAM-1, ICAM-2, ICAM-3 in CSF suggest their important role in inflammatory process of viral and bacterial origin. In NB group, the serum concentrations of sICAM-1, sICAM-2 were significantly increased before and after treatment in comparison with control as well as with the analogous test results in TBE group. It may suggest NB as the part of systemic inflammation. The CSF concentration of sICAM-2 decreases after treatment in NB group in comparison with the analogous test results of TBE group. The increased CSF concentration of sICAM-2 in TBE group when compared to the CSF concentration in NB group suggest slow recovery and still persisting immunological activation in this group, even when the neurological symptoms disappeared. Increased concentrations in CSF in both diseases indicate intrameningeal activity of lymphocytes and may be a useful marker of inflammation.
authors.affiliation: Klinika Chorób Zakaźnych i Neuroinfekcji Akademii Medycznej, Białymstoku. zajkowsk@kki.pl
authors.forename: Joanna M
authors.initials: JM
authors.lastname: Zajkowska
authors.forename: Aneta
authors.initials: A
authors.lastname: Izycka
authors.forename: Ewa
authors.initials: E
authors.lastname: Jabłońska
authors.forename: Teresa
authors.initials: T
authors.lastname: Hermanowska-Szpakowicz
authors.forename: Maciej
authors.initials: M
authors.lastname: Kondrusik
authors.forename: Sławomir
authors.initials: S
authors.lastname: Pancewicz
authors.forename: Sambor
authors.initials: S
authors.lastname: Grygorczuk
authors.forename: Renata
authors.initials: R
authors.lastname: Swierzbińska
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood / Q000134:cerebrospinal fluid; D016022:Case-Control Studies; D015815:Cell Adhesion Molecules / Q000097:blood / Q000134:cerebrospinal fluid; D004675:Encephalitis, Tick-Borne / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood / Q000134:cerebrospinal fluid; D020852:Lyme Neuroborreliosis / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; D015815:Cell Adhesion Molecules; C065289:ICAM2 protein, human; C483616:ICAM3 protein, human; D018799:Intercellular Adhesion Molecule-1